The Goldman Sachs Group started coverage on shares of Beta Bionics (NASDAQ:BBNX - Free Report) in a research report sent to investors on Friday morning, Marketbeat.com reports. The firm issued a neutral rating and a $16.00 target price on the stock.
Several other equities research analysts also recently commented on BBNX. LADENBURG THALM/SH SH started coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a "neutral" rating and a $20.00 price objective on the stock. Bank of America started coverage on shares of Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating on the stock. Lake Street Capital started coverage on shares of Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating and a $30.00 target price on the stock. Robert W. Baird initiated coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a "neutral" rating and a $20.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Beta Bionics in a report on Monday, February 24th. They issued a "buy" rating and a $25.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Beta Bionics has a consensus rating of "Moderate Buy" and an average target price of $23.13.
Read Our Latest Report on Beta Bionics
Beta Bionics Price Performance
Shares of NASDAQ BBNX traded up $1.84 during trading on Friday, hitting $17.20. The stock had a trading volume of 1,228,265 shares, compared to its average volume of 485,303. The company's fifty day moving average price is $12.38. Beta Bionics has a 12 month low of $8.89 and a 12 month high of $24.50.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.01).
Institutional Trading of Beta Bionics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BBNX. Eventide Asset Management LLC purchased a new position in Beta Bionics during the first quarter valued at $60,307,000. Wellington Management Group LLP purchased a new stake in shares of Beta Bionics during the 1st quarter worth approximately $47,346,000. Sands Capital Ventures LLC purchased a new stake in shares of Beta Bionics during the 1st quarter worth approximately $37,990,000. Omega Fund Management LLC bought a new position in shares of Beta Bionics during the 1st quarter valued at approximately $24,337,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Beta Bionics during the 1st quarter valued at approximately $10,799,000.
Beta Bionics Company Profile
(
Get Free Report)
Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Read More
Before you consider Beta Bionics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.
While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
